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Options
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PGY-2 Critical Care Resident
Baptist Hospital of Miami
KamarenaS@BaptistHealth.Net
Disclosures
The author of this presentation has no 
relevant financial or non-financial 
relationships in the products described 
and reviewed in this presentation. 
Objectives
➢ Describe current treatment strategies for epilepsy
➢ Introduce new treatment options for epilepsy
➢ Discuss the impact of legislation on patient 
access to these new therapies
What is a Seizure?
➢ A seizure occurs when brain cells misfire 
and stop working the way they are 
supposed to, sending too many electrical 
signals at one time
➢ These uncontrolled electrical signals cause 
a change in awareness, movement or 
sensation
International League Against Epilepsy
Pathophysiology
➢ Excitation through glutamate
➢ Inhibition through gamma-Aminobutyric acid (GABA)
Source: http://pedsinreview.aappublications.org/content/pedsinreview/19/10/342/F2.large
Pathophysiology
Source: http://pedsinreview.aappublications.org/content/pedsinreview/19/10/342/F2.large.jpg
http://pedsinreview.aappublications.org/content/pedsinreview/19/10/342/F6.large.jpg
Diagnosis of Seizures
Source: https://jnnp.bmj.com/content/jnnp/76/suppl_3/iii2/F5.large.jpg
Diagnosis of Seizures
Source: https://www.mountnittany.org/assets/images/krames/Image_201608102119_205.jpg
What is Epilepsy?
➢ At least two unprovoked (or reflex) 
seizures occurring greater than 24 hours 
apart
➢One unprovoked (or reflex) seizure and a 
probability of further seizures similar to 
the general recurrence risk (at least 60%) 
after two unprovoked seizures, occurring 
over the next 10 years
➢Diagnosis of an epilepsy syndrome
International League Against Epilepsy
Facts About Epilepsy
➢ Causes: head injuries, infections, strokes, 
birth defects, and brain tumors
➢~50 million people worldwide have 
epilepsy
➢ 2.4 million people are newly diagnosed 
each year
➢~70% of people respond to treatment
➢ Epilepsy is not hereditary, but genetics 
sometimes plays a role
World Health Organization
A few known people with 
Epilepsy
➢Julius Caesar
➢Michelangelo
➢Ludwig Van Beethoven
➢Thomas Edison
➢Leonardo Da Vinci
➢Charles Dickens
➢Edgar Allan Poe
➢Adam Horowitz – Beastie  Boys
➢Amy Lee – Evanescence
➢Neil Young 
➢Jonathan Davis - Korn
➢Susan Boyle
➢Prince
➢ Lindsey Buckingham –
Fleetwood Mac
➢ Danny Glover
➢ Hugo Weaving – Matrix, Lord 
of the Rings, Captain America
➢ Dai Greene – Olympian
➢ Jason Snelling- NFL
➢ Alan Fonseca- NFL
➢ John Roberts – Supreme 
Court Justice
➢ Melanie Griffith – Actress
Types of Seizures
Types of Seizures
Fisher, Robert S., et al. "Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification 
and Terminology." Epilepsia 58.4 (2017): 522-530.
Types of Seizures
Fisher, Robert S., et al. "Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification 
and Terminology." Epilepsia 58.4 (2017): 522-530.
Timeline of Antiepileptics
1st
Generation
1912 Phenobarbital
1939 Phenytoin
1953 Carbamazepine
1958 Ethosuximide
1963 Sodium Valproate
2nd
Generation
1993 Felbamate and Gabapentin
1994 Lamotrigine
1996 Topiramate and Tiagabine
1999 Levetiracetam
2000 Oxcarbazepine and 
Zonisamide
Source: Preceden. Accessed from https://www.preceden.com/timelines/28748-epilepsy-timeline on 2018 Dec 11. 
Recent Antiepileptics
2005 Pregabalin
2008 Rufinamide
2009 Vigabatrin and Lacosamide
2011 Clobazam
2012 Perampanel
2013 Eslicarbazepine
2016 Brivaracetam
2018 Cannabidiol Solution
Source: Skelton, J B., et al. J. Am. Pharm. Assoc. 2017 vol. 57, no. 4.
Guidelines for Treatment
➢ Adults with New Onset Epilepsy with Focal 
Epilepsy or Unclassified Tonic-Clonic Seizures 
Monotherapy
● Lamotrigine may be considered to decrease seizure 
frequency (Level B)
● Leviteracetam and Zonisamide may be considered to 
decrease seizure frequency (Level C)
● Gabapentin may be considered in patients ≥60 years 
old to decrease seizure frequency (Level C)
● Vigabatrin toxicity profile precludes it as 1st line 
therapy (Level C)
● Pregabalin use at 150 mg/day is possibly less 
efficacious than Lamotrigine use at 100 mg/day 
(Level C)
Kanner, Andres M., et al. "Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, 
Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society." Neurology (2018): 10-1212.
Guidelines for Treatment
➢ Recommendation for Childhood Absence Epilepsy
● Unless there are compelling reasons based on adverse 
events profile, ethosuximide or valproic acid use 
should be considered before lamotrigine use to 
decrease seizure frequency in treating absence seizures 
in childhood absence epilepsy (Level B)
Kanner, Andres M., et al. "Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, 
Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society." Neurology (2018): 10-1212.
Guidelines for Treatment
➢ Adults with Treatment-Resistant Focal Epilepsy 
Monotherapy
● Eslicarbazepine use may be considered to decrease 
seizure frequency as monotherapy (Level C)
➢ Adults and Pediatric Patients with Treatment-
Resistant Generalized Epilepsy - Adjunctive
● IR and ER lamotrigine use should be considered as add-
on therapy in treating adults with TR generalized tonic-
clonic seizures secondary to GE (Level B)
● Levetiracetam use should be considered to decrease 
seizure frequency as add-on therapy for TR GTC seizures 
and for TR juvenile myoclonic epilepsy
Kanner, Andres M., et al. "Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, 
Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society." Neurology (2018): 10-1212.
Guidelines for Treatment
➢ Adults with Treatment-Resistant Focal Epilepsy 
Adjunctive Therapy
● Immediate-release pregabalin and perampanel are 
established as effective to reduce seizure frequency
● (Level A)
● Vigabatrin and rufinamide should be considered 
established as effective for decreasing seizure frequency 
but are not first-line agents (retinopathy risk with VGB 
and modest benefit with RFN) (Level A)
● Lacosamide, eslicarbazepine, and extended-release 
topiramate use should also be considered to decrease 
seizure frequency in this population (Level B)
● Clobazam and extended-release oxcarbazepine use may 
be considered to decrease seizure frequency (Level C)
Kanner, Andres M., et al. "Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, 
Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society." Neurology (2018): 10-1212.
Guidelines for Treatment
➢ Adults and Pediatric Patients with Lennox-Gastaut
Syndrome – Adjunctive Therapy
● Rufinamide use should be considered established as 
effective as add-on therapy (Level A)
● Clobazam should be considered (Level B)
➢ Pediatric Patients with Treatment Resistant Focal 
Epilepsy – Adjunctive Therapy
● Levetiracetam should be considered (Level B for ages 
1 month to 16 years)
● Zonisamide use should be considered (Level B)
● Oxcarbazepine use should be considered (Level B)
Kanner, Andres M., et al. "Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, 
Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society." Neurology (2018): 10-1212.
Principles of AED Selection
➢ After a first seizure, a majority of patients are 
not placed on AEDs
➢ Medications are first line therapy for treatment
➢ Patients are started on AED monotherapy and 
adjunctive therapy is added if treatment fails
➢ ~60% of patients will respond to the first two 
AEDs tried
➢ Medications must be selected based on a number 
of factors, from type of epilepsy, to factors like 
patient adherence and insurance coverage
Berg A. (2008). Risk of recurrence after a first unprovoked seizure. Epilepsia 49(Suppl. 1), 13‐18. doi: 10.1111/j.1528‐1167.2008.01444.x
Krumholz A, et al. (2007). Practice parameter: Evaluating an apparent unprovoked first seizure in adults (an evidence‐based review): Report of the Quality Standards Subcommittee of the 
American Academy of Neurology and the American Epilepsy Society. Neurology, 69(21),1996‐2007.
Pharmacological 
Therapy
Pregabalin (pre-gab-a-lin)
Lyrica®
Class Gabapentinoid
Dose 
Range
150 mg daily in 2-3 
doses, Max: 600 mg 
daily
Capsules, ER Tablets, 
Oral Solution
Seizure 
Types
Lennox-Gastaut
Syndrome (adjunctive, 
off label)
Source: Lyrica (pregabalin) [prescribing information]. New York, NY: Pfizer Inc; May 2018.
https://upload.wikimedia.org/wikipedia/commons/thumb/d/db/Gabapentinoid-structures.png/300px-Gabapentinoid-structures.png
Pregabalin
Lyrica®
MOA Binds α-2-δ subunit of 
voltage-gated Ca2+ channels 
modulating Ca2+ influx at 
the nerve terminals. Inhibits 
excitatory neurotransmitter 
release including glutamate, 
norepinephrine, serotonin, 
dopamine, substance P, and 
calcitonin gene-related 
peptide 
Source: Lyrica (pregabalin) [prescribing information]. New York, NY: Pfizer Inc; May 2018.
http://www.ajhp.org/content/ajhp/64/14/1475/F2.large.jpg
Pregabalin
Lyrica®
Side 
Effects
Peripheral edema, weight gain, xerostomia, visual 
disturbances, suicidal ideation
Caution Renally adjusted, multiple indications
CI Hypersensitivity to pregabalin
Source: Lyrica (pregabalin) [prescribing information]. New York, NY: Pfizer Inc; May 2018.
Pregabalin
➢ Cost
● $8.92/capsule
➢ Monitoring
● None
➢ Pregnancy Category
● Pregabalin crosses the placenta
● Secreted in breast milk (RID ~7%) 
● Temporarily decreases sperm concentrations
➢ Renal Cutoff
● CrCl = 60 mL/min
Source: Lyrica (pregabalin) [prescribing information]. New York, NY: Pfizer Inc; May 2018.
Pregabalin
➢ Place in Therapy
● Level A – Treatment Resistant 
Focal Epilepsy
● Adjunctive Therapy in Adults
● Immediate release 
● Level C – New Onset Epilepsy 
with Focal Epilepsy or Unclassified 
Tonic-Clonic Seizures
• Monotherapy in Adults
• Recommendation against
• Lamotrigine is better
Rufinamide (ruh-fin-ah-mide)
Banzel®
Class Triazole Derivative
Dose 
Range
400 to 800 mg daily 
in 2-3 doses, Max: 
3,200 mg daily
Tablets, Suspension
Seizure 
Types
Lennox-Gastaut
(adjunctive, FDA 
approved)
Source: Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2015.
https://images.rxlist.com/images/multum/628560582_pb.jpg
Rufinamide
Banzel®
MOA Exact mechanism is unknown
In vitro, prolongs inactive state of Na+ Channels
Source: Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2015.
https://upload.wikimedia.org/wikipedia/commons/thumb/e/e5/Rufinamide.svg/1200px-Rufinamide.svg.png
Rufinamide
Banzel®
Side 
Effects
Shortened QT (46-65%), Multiorgan Sensitivity 
Reactions, Suicidal Ideation
Caution Renally adjusted, if concomitant Valproate starting dose 
of Rufinamide should be <400 mg/day
CI Patients with familial short QT syndrome, 
Hypersensitivity to Rufinamide
Source: Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2015.
Rufinamide
➢ Cost
● 200 mg tablet - $13.84
● 400 mg tablet - $27.68
➢ Monitoring
● None
➢ Pregnancy Category
● C- Adverse effects in animal studies
● Hormonal contraceptives less effective
● Milk excretion unknown
➢ Hepatic Cutoff
● Severe Impairment – Not recommended
Source: Banzel (rufinamide) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; June 2015.
Rufinamide
➢ Place in Therapy
● Level A – Treatment Resistant Focal 
Epilepsy
• Adjunctive Therapy in Adults
• Not first line 
● Level A - Lennox-Gastaut Syndrome
• Adjunctive Therapy in Adults and Pediatrics
• Effective as add-on therapy
Vigabatrin (vih-gab-ah-trin)
Sabril®
Class Structural analogue of GABA
Dose 
Range
500 mg BID, Recommended dose: 1.5 g BID
Tablets, Packet
Seizure 
Types
Refractory complex partial seizures (FDA approved)
Source: Sabril (vigabatrin) [prescribing information]. Deerfield, IL: Lundbeck; February 2018.
https://upload.wikimedia.org/wikipedia/commons/thumb/0/04/Vigabatrin2DCSD.svg/1200px-Vigabatrin2DCSD.svg.png
Vigabatrin
Sabril®
MOA Irreversibly inhibits gamma-aminobutyric acid 
transaminase (GABA-T), increasing the levels of the 
inhibitory compound gamma amino butyric acid (GABA) 
within the brain. Duration of effect is dependent upon rate 
of patient GABA-T resynthesis.
Source: Sabril (vigabatrin) [prescribing information]. Deerfield, IL: Lundbeck; February 2018.
http://assets.markallengroup.com/article-images/image-library/147/Fig8blood.jpg
Vigabatrin
Sabril®
Side 
Effects
Viral Infection (20% in infants), Irritability (16-23% in 
infants), Tremor (15%), Visual field loss (≥30%), 
Nystagmus, Blurred vision, Otitis media (10-44% 
infants), URTI (7%), Fever (4%)
Caution Vision Loss (Black Box Warning), REMS
CI Hypersensitivity to Vigabatrin
Source: Sabril (vigabatrin) [prescribing information]. Deerfield, IL: Lundbeck; February 2018.
Vigabatrin
➢ Cost
● $126.64 – $159.55 per 500 mg
➢ Monitoring
● Vision assessments (4 weeks, 3 months)
➢ Pregnancy Category
● C – Adverse events in animal studies
● Crosses placenta
● Birth defects – Limb defects, male genital 
malformations, fetal anticonvulsant 
syndrome, renal and ear abnormalities
➢ Renal Cutoff
● 80 mL/min
Source: Sabril (vigabatrin) [prescribing information]. Deerfield, IL: Lundbeck; February 2018.
Vigabatrin
➢ Place in therapy
● Level A – Treatment Resistant Focal 
Epilepsy
• Adjunctive Therapy in Adults
• Not first line – Vision loss
● Level C - New Onset Epilepsy with 
Focal Epilepsy or Unclassified Tonic-
Clonic Seizures
• Monotherapy in Adults
• Not first line
Lacosamide (la-KOE-sa-mide)
Vimpat®
Class Functionalized Amino Acid
Dose 
Range
Monotherapy: 100 mg BID, can increase by 50 mg BID
OR
200 mg LD f/b 100 mg BID, can increase by 50 mg BID
Adjunctive: 50 mg BID, can increase by 50 mg BID
Seizure 
Types
Partial onset seizure (monotherapy or adjunctive, FDA 
approved)
Status epilepticus, refractory
Source: Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; November 2018.
Lacosamide
Vimpat®
MOA In vitro, stabilizes hyper 
excitable neuronal 
membranes and inhibits 
repetitive neuronal firing 
by enhancing the slow 
inactivation of sodium 
channels
Source: Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; November 2018.
https://openi.nlm.nih.gov/imgs/512/329/3759704/PMC3759704_nyas1291-0056-f1.png
Lacosamide
Vimpat®
Side 
Effects
Dizziness, Fatigue, Ataxia, Headache, N/V, Tremor, 
Diplopia, Blurred vision
Caution PR interval prolongation, cardiac arrhythmia, AV block, V 
Tach, Multiorgan hypersensitivity, DRESS, Blurred vision, 
Diplopia, Suicidal ideation
CI Hypersensitivity to Lacosamide
Source: Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; November 2018.
https://upload.wikimedia.org/wikipedia/commons/thumb/d/d8/Lacosamide.svg/1200px-Lacosamide.svg.png
Lacosamide
➢ Cost
● $10.33 – 50 mg, $16.16 – 100 mg, 
$17.11 – 150-200 mg
➢ Monitoring
● Initial ECG in patients with cardiac 
issues
➢ Pregnancy Category
● Adverse events in animal studies
➢ Renal Cutoff
● 30 mL/min
Source: Vimpat (lacosamide) [prescribing information]. Smyrna, GA: UCB Inc; November 2018.
Lacosamide
➢ Place in therapy
● Level B – Treatment Resistant Focal 
Epilepsy
• Adjunctive Therapy in Adults
• Should be considered
Clobazam
Onfi®
Class Benzodiazepine
Dose 
Range
Complex, see next slide
Tablets, Solution
Seizure 
Types
Lennox-Gastaut
(adjunctive, FDA Approved)
Source: Onfi (clobazam) [prescribing information]. Deerfield, IL: Lundbeck; June 2018.
https://upload.wikimedia.org/wikipedia/commons/thumb/f/f3/Clobazam_structure.svg/1200px-Clobazam_structure.svg.png
Clobazam
Onfi®
MOA Binds receptors the 
postsynaptic GABA neuron 
at several sites within the 
CNS. Enhances inhibitory 
effect of GABA on neuronal 
excitability by increased 
neuronal membrane 
permeability to chloride 
ions. This shift in chloride 
ions results in 
hyperpolarization (a less 
excitable state) and 
stabilization
Source: Onfi (clobazam) [prescribing information]. Deerfield, IL: Lundbeck; June 2018.
https://img.medscapestatic.com/pi/meds/ckb/94/7194tn.jpg
Clobazam
Onfi®
Side 
Effects
Drooling (13-14%), Aggressive Behavior(8-14%), URTI 
(13-14%), Fever (10-17%), SJS, TEN
Caution Anterograde Amnesia, SJS/TEN in first 8 weeks, Suicidal 
Ideation
CI Hypersensitivity to Clobazam
Source: Onfi (clobazam) [prescribing information]. Deerfield, IL: Lundbeck; June 2018.
Clobazam Dosing
➢ >30 kg: Initial: 5 mg twice daily for ≥1 week, then 
increase to 10 mg twice daily for ≥1 week, then increase to 
20 mg twice daily thereafter
➢ ≤30 kg: Initial: 5 mg once daily for ≥1 week, then increase 
to 5 mg twice daily for ≥1 week, then increase to 10 mg 
twice daily thereafter
➢ CYP2C19 poor metabolizers:
● ≤30 kg: Initial: 5 mg once daily for ≥1 week, then increase to 5 mg 
twice daily; after ≥1 week may increase to 10 mg twice daily
● >30 kg: Initial: 5 mg once daily for ≥1 week, then increase to 5 mg 
twice daily for ≥1 week, then increase to 10 mg twice daily; after ≥1 
week may increase to 20 mg twice daily
Source: Onfi (clobazam) [prescribing information]. Deerfield, IL: Lundbeck; June 2018.
Clobazam Dosing
➢ Cost
• Solution - $0.80 per 2.5 mg
• Tablets - 10 mg - $2.29-21.97, 20 mg - $4.53-
43.93
➢ Monitoring
• Serious Skin Reactions
➢ Pregnancy Category
• Crosses the placenta
• Increased fetal malformations in 1st trimester
➢ Hepatic Cutoff
• Adjusted in mild to moderate hepatic impairment
Source: Onfi (clobazam) [prescribing information]. Deerfield, IL: Lundbeck; June 2018.
Clobazam Dosing
➢ Place in therapy
● Level C – Treatment Resistant Focal 
Epilepsy
• Adjunctive Therapy in Adults
• May be considered
● Level B - Lennox-Gastaut Syndrome
• Adjunctive Therapy in Adults and 
Pediatrics
• Should be considered
Perampanel
Fycompa®
Class AMPA Glutamate Receptor Antagonist
Dose 
Range
Patients not on enzyme inducing therapy:2 mg daily HS 
Increase by 2 mg daily. Up to 12 mg daily HS
Patients on enzyme inducing therapy: 4 mg daily HS 
Increase by 2 mg daily. Up to 12 mg daily HS
Tablets, Solution
Seizure 
Types
Partial Onset Seizure w/ or w/o secondarily generalized 
seizure (FDA approved)
Primary generalized tonic-clonic seizures (adjunctive, FDA 
approved)
Source: Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2018.
Perampanel
Fycompa®
MOA Exact mechanism unknown. It is a noncompetitive 
antagonist of AMPA glutamate receptor postsynaptically.
Source: Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2018.
Source: https://qtxasset.com/styles/breakpoint_sm_default_480px_w/s3/2016-
06/fycompa.JPG?jeJtzbE7kmvMC8yjAac.b4idRU.DMfAa&itok=0Ll1zZIe
Perampanel
Fycompa®
Side 
Effects
Peripheral Edema (2%), Dizziness (16-≤47%), Hostility 
(≤12%-≤20%), Aggressive Behavior (2%-≤20%),
delusion, disorientation, emotional lability, homicidal 
ideation, paranoia, psychiatric disturbance (worsening)
Caution Black Box Warning: Serious Psychiatric and Behavioral 
Reactions
CI Hypersensitivity to Perampanel
Source: Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2018.
Perampanel
➢ Cost
• Tablet - 2 mg - $18.08 – 4, 6, 8, 10, 12 mg -
$35.88
➢ Monitoring
• Suicidal thoughts, depression, behavioral 
changes during therapy and for 1 month after 
D/C
➢ Pregnancy Category
➢ Adverse events in animal studies
➢ Contraceptives containing levonorgestrel may 
be less effective
➢ Renal Cutoff
➢ <50 mL/min
Source: Fycompa (perampanel) [prescribing information]. Woodcliff Lake, NJ: Eisai Inc; September 2018.
Perampanel
➢ Place in therapy
● Level A – Treatment Resistant Focal 
Epilepsy
• Adjunctive Therapy in Adults
• Established as effective
Eslicarbazepine
(Es-li-kar-baz-e-peen)
Aptiom®
Dose 
Range
Initial: 400 or 800 mg PO QD. Titrate weekly in 400-600 
mg increments.
Maintenance: 800-1,600 mg QD.
Monotherapy: Consider 800 mg QD 1,200 mg QD if not 
tolerating.
Adjunctive Therapy: Consider 1,200 mg QD - 1,600 mg 
QD if inadequate seizure response.
Seizure 
Types
Partial Onset Seizure (FDA approved)
Source: Aptiom (eslicarbazepine) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; October 2017.
Eslicarbazepine
Aptiom®
MOA A precise mechanism has not been defined, but is thought 
to involve inhibition of voltage-gated sodium channels.
Source: Aptiom (eslicarbazepine) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; October 2017.
https://img.medscapestatic.com/pi/features/drugdirectory/octupdate/SPI02060.jpg
Eslicarbazepine
Aptiom®
Side 
Effects
Dizziness, Drowsiness, Nausea, Diplopia (9-11%)
Caution Hazardous agent (NIOSH 2016 group 3), use gloves 
when handling, unpacking, or placing in storage.
Increased risk of visual changes and coordination 
abnormalities during titration period in patients >60
Risk for SJS, multiorgan hypersensitivity reactions, 
DRESS
Dose dependent decreases in T3 and T4 values
CI Hypersensitivity to Eslicarbazepine, Oxacarbazepine
Source: Aptiom (eslicarbazepine) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; October 2017.
Eslicarbazepine
➢ Cost
➢ Tablet – 200-800 mg - $36.71
➢ Monitoring
➢ Sodium during maintenance if patient 
receiving other sodium depleting drugs
➢ Pregnancy Category
➢ Adverse events in animal studies
➢ May decrease plasma levels of hormonal 
contraceptives
➢ Excreted in breast milk
➢ Renal Cutoff
➢ <50 mL/min
Source: Aptiom (eslicarbazepine) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals; October 2017.
Eslicarbazepine
Eslicarbazepine
➢ Place in therapy
● Level C – Treatment Resistant Focal 
Epilepsy
• Monotherapy in Adults
• May be considered
● Level B – Treatment Resistant Focal 
Epilepsy
• Adjunctive Therapy in Adults
• Should be considered
Brivaracetam
(Briv-a-ra-se-tam)
Briviact®
Class Racetam Derivative/Analogue of Leviteracetam
Dose 
Range
Monotherapy and Adjunctive:
50 mg BID initially, may decrease to 25 mg BID or 
increase to 100 mg BID based on response and 
tolerability
Maximum dose: 200 mg total daily
If used with Rifampin, double the dose. 
Major substrate of 2C19
Seizure 
Types
Partial onset seizures (FDA approved)
Source: Briviact (brivaracetam) [prescribing information]. Smyrna, GA: UCB; May 2018.
Brivaracetam
Briviact®
MOA Unknown. High selectivity for synaptic vesicle protein 2A 
(same protein as leviteracetam) with a 20x more affinity
Source: Briviact (brivaracetam) [prescribing information]. Smyrna, GA: UCB; May 2018.
https://img.medscapestatic.com/pi/features/drugdirectory/octupdate/UCB07700.jpg
Brivaracetam
Briviact®
Side 
Effects
Drowsiness, Fatigue, Hypersomnia, Malaise, Abnormal 
Gait, Ataxia, Equilibrium disturbance, Vertigo, Psychotic 
and Nonpsychotic Psychiatric Disturbances (13%), 
Asthenia, Nystagmus
Caution Must be tapered off, Hematologic abnormalities, 
Psychiatric disturbances
CI Hypersensitivity to Brivaracetam
Source: Briviact (brivaracetam) [prescribing information]. Smyrna, GA: UCB; May 2018.
Brivaracetam
➢ Cost
➢ IV – 50 mg/mL – $11.01
➢ Solution – 10 mg/mL - $4.28
➢ Tablet – 10, 25, 50, 75, 100 mg - $21.40
➢ Monitoring
➢ CBC, liver and renal function, depression, and 
suicidality (baseline and if clinically indicated)
➢ Pregnancy Category
➢ Adverse events in animal studies
➢ Hepatic Cutoff
➢ Mild to severe – Start at 25 mg, Maximum 
dose of 75 mg
Source: Briviact (brivaracetam) [prescribing information]. Smyrna, GA: UCB; May 2018.
Brivaracetam
➢ Place in therapy
● ?
Cannibidiol Solution

Cannabidiol Solution
Epidiolex®
Class Phytocannabinoid
Dose 
Range
2.5 mg/kg BID, after 1 week may increase to 5 mg/kg BID
May increase in weekly increments of 2.5 mg/kg BID
Maximum Dose: 10 mg/kg BID
Oral Solution
Seizure 
Types
Lennox-Gastaut in patients 2 years or older (FDA Approved)
Dravet Syndrome in patients 2 years or older(FDA Approved)
MOA Unknown. It does not appear to involve its effects on cannabinoid 
receptors.
Side 
Effects
Somnolence, Decreased Appetite, Diarrhea, Transaminase Elevations, 
Fatigue, Malaise, Asthenia, Rash, Insomnia, Sleep Disorder, Poor Quality 
of Sleep, Infections
Caution Taper Off, Hepatically adjusted, 20 mg/kg/day resulted in greater 
reduction in seizure rates but had increases in adverse drug reactions
CI Hypersensitivity to cannabidiol
Cannabidiol Solution
➢ Cost
➢ Solution 100 mg/mL - $14.82
➢ (75 kg $55.56 - $222.30 per day)
➢ Monitoring
➢ ALT, AST, bilirubin (0, 1, 3, and 6 months)
➢ Periodic monitoring as clinically indicated (dose 
change or starting hepatotoxic drug or clinical 
signs of hepatic dysfunction)
➢ Pregnancy Category
➢ Adverse events in animal studies
➢ Cannabidiol can be detected in the umbilical 
cord and meconium following maternal use of 
inhaled, non-medicinal cannabis during 
pregnancy 
Source: Epidiolex (cannabidiol) [prescribing information]. Carlsbad, CA: Greenwich Biosciences, Inc; September 2018.
Cannabidiol Solution
➢ Hepatic Cutoff
➢ Moderate – Start at 1.25 mg/kg BID with 
slow increases
➢ Severe – Start at 0.5 mg/kg BID with slow 
increases
➢ Hepatotoxicity during treatment:
➢ AST and/or ALT >3 times ULN and total 
bilirubin >2 times ULN: Discontinue 
treatment.
➢ Sustained AST and/or ALT >5 times ULN: 
Discontinue treatment.
Source: Epidiolex (cannabidiol) [prescribing information]. Carlsbad, CA: Greenwich Biosciences, Inc; September 2018.
Cannabidiol Solution
➢ Place in therapy
● ?
Cannabidiol Legality
Non Pharmacological 
Therapy
Epilepsy Surgery
➢ Focal Resection
● Temporal Lobe 
Resection
● Frontal, Parietal, 
Occiptal Lobe 
Resection
➢ Lesionectomy
➢ Laser Interstitial 
Thermal Therapy
➢ Anatomical or 
Functional 
Hemispherectomy/
Hemispherotomy
➢ Corpus Callostomy
➢ Stereotactic 
Radiosurgery
Epilepsy Surgery
Source: https://mayfieldclinic.com/Images/pe-epilepsy-surgery-fig3.jpg
https://my.clevelandclinic.org/-/scassets/ad37970506424f408a6aa3c46f5596cc.ashx
Neurostimulation Devices
➢Vagus Nerve Stimulation (VNS)
Source: https://neuromodec.com/wp-content/uploads/2016/08/VNS.jpg 
https://www.aans.org/-/media/Images/AANS/Neurosurgical-Conditions-and-
Treatments/Lead_Vagus_Nerve_Stimulation.ashx?la=en&hash=FDCC6C03258B04D3BFE1E18B2F853D18AE6959E2
https://www.sciencesource.com/Doc/TR1_WATERMARKED/f/6/7/c/SS2758135.jpg?d63644360461
http://eu.cyberonics.com/static/images/27.jpg
Neurostimulation Devices
➢Responsive Neurostimulation (RNS)
Source: https://www.pnas.org/content/pnas/112/49/15012/F2.large.jpg
Neurostimulation Devices
➢Deep Brain Stimulation (DBS)
Source: http://www.parkinson.fo/myndir/myndin-162_r_960_620.jpg
Conclusion
➢ Since 2000, many new AEDs have been brought to 
market
● Each has a place in managing epilepsy
➢ Epidiolex is the first FDA approved CBD derivative 
for treatment of Epilepsy
● It is the only CBD derivative to be placed into Schedule V
➢ For treatment resistant epilepsy, we have newer 
medications as well as surgical and implantable 
means of managing the condition
Test Your Knowledge
1. True or False: Epidiolex (cannabidiol/CBD) is the first 
purified drug substance derived from marijuana to be 
FDA approved in the U.S.
2. True or False: Epidiolex (cannabidiol/CBD) has been 
placed into Schedule I by the DEA.
3. True or False: After the first seizure episode, a 
patient should be initiated on antiseizure therapy.

